US equities |
NVDA $238.79 ▲+2.07% SPCX $167.72 ▲+5.51% MU $1,061.55 ▼-1.24% TSLA $379.99 ▲+2.54% MSFT $526.88 ▲+1.81% SNDK $1,700.40 ▼-1.14% INTC $116.66 ▼-2.24% META $742.67 ▲+2.00%
FinancialContent

Kezar Life Sciences, Inc. - Common Stock (NQ:KZR)

7.290 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 8, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kezar Life Sciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Halper Sadeh LLC is Investigating Whether KZR, QXO, SKYT are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Halper Sadeh LLC is Investigating Whether APLS, CNTA, KZR, EQH are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Shareholder Alert: Ademi LLP investigates whether Kezar Life Sciences, Inc. is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
KZR Stock Alert: Halper Sadeh LLC is Investigating Whether Kezar Life Sciences, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right
From Aurinia Pharmaceuticals Inc.
Via Business Wire
News headline image
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
From Enodia Therapeutics and Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2025 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Launches Strategic Review As FDA Roadblock Derails Liver Drug Plans ↗
Kezar Life Sciences faces FDA delays for AIH drug trials, implements restructuring, and explores strategic alternatives amid potential acquisition interest. 
Via Benzinga
News headline image
Kezar Life Sciences Stock Hit With Downgrades And Price Target Cuts: Retail Keeps Hopes Alive ↗
Kezar announced on Thursday that it was unable to align with the FDA on a potential registrational clinical trial of Zetomipzomib in patients with relapsed and refractory autoimmune hepatitis. 
Via Stocktwits
Topics Workforce
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
This Booz Allen Hamilton Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in Two Upcoming Investor Conferences
From Kezar Life Sciences
Via Business Wire
News headline image
Kezar Narrows Loss 37 Percent in Q2 ↗
Via The Motley Fool
News headline image
Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
FDA Lifts Pause On Kezar's Liver Drug Trial—Next Stop Lupus Study ↗
Kezar Life Sciences' zetomipzomib trial in autoimmune hepatitis resumes as FDA lifts partial hold following a favorable safety review. 
Via Benzinga
News headline image
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Touts Positive Data From Mid-Stage Study For Chronic Liver Disease Drug Candidate ↗
Kezar Life Sciences reports positive Phase 2a data for zetomipzomib in autoimmune hepatitis, showing higher response rates and reduced steroid use. 
Via Benzinga
News headline image
Kezar Life Sciences Announces Positive Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis (AIH) and Reports Fourth Quarter and Year End 2024 Financial Results
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present Topline Results from the PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis on March 25, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences to Present at Virtual KOL Event Hosted by William Blair on Zetomipzomib Clinical Development in Autoimmune Hepatitis and Provide a Safety Update from the PALIZADE Trial for Lupus Nephritis on February 27, 2025
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update
From Kezar Life Sciences, Inc.
Via Business Wire
News headline image
Glancy Prongay & Murray LLP Announces Investigation of Kezar Life Sciences, Inc. (KZR)
From Glancy Prongay & Murray LLP
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >